SEARCH

SEARCH BY CITATION

References

  • 1
    Kuijper EJ, Wilcox MW. Decreased effectiveness of metronidazole for the treatment of Clostridium difficile infection? Clin Infect Dis 2008; 47: 6365.
  • 2
    O’Donnell LJD, Virjee J, Heaton KW. Detection of pseudodiarrhoea by simple clinical assessment of intestinal transit rate. BMJ 1990; 300: 439440.
  • 3
    McDonald LC, Coignard B, Dubberke E, Song X, Horan T, Kutty PK. Recommendations for surveillance of Clostridium difficile-associated disease. Infect Control Hosp Epidemiol 2007; 28: 140145.
  • 4
    Kuijper EJ, Coignard B, Tull P. Emergence of Clostridium difficile-associated disease in North America and Europe. Clin Microbiol Infect 2006; 12 (suppl 6): 218.
  • 5
    Tal S, Gurevich A, Guller V, Gurevich I, Berger D, Levi S. Risk factors for recurrence for Clostridium difficile-associated diarrhea in the elderly. Scand J Infect Dis 2002; 34: 594597.
  • 6
    Zar FA, Bakkanagari SR, Moorthi KM, Davis MB. A comparison of vancomycin and metronidazole for the treatment of Clostridium difficile–associated diarrhea, stratified by disease severity. Clin Infect Dis 2007; 45: 302307.
  • 7
    McFarland LV, Elmer GW, Surawicz CM. Breaking the cycle: treatment strategies for 163 cases of recurrent Clostridium difficile disease. Am J Gastroenterol 2002; 97: 17691775.
    Direct Link:
  • 8
    Moshkowitz M, Ben-Baruch E, Kline Z, Shimoni Z, Niven M, Konikoff F. Risk factors for severity and relapse of pseudomembranous colitis in an elderly population. Colorectal Dis 2007; 9: 173177.
  • 9
    Pépin J, Alary ME, Valiquette L et al. Increasing risk of relapse after treatment of Clostridium difficile colitis in Quebec, Canada. Clin Infect Dis 2005; 40: 15911597.
  • 10
    Nair S, Yadav D, Corpuz M, Pitchumoni CS. Clostridium difficile colitis: factors influencing treatment failure and relapse – a prospective evaluation. Am J Gastroenterol 1998; 93: 18731876.
  • 11
    Fernandez A, Anand G, Friedenberg F. Factors asscoiated with failure of metronidazole in Clostridium difficile-associated disease. J Clin Gastroenterol 2004; 38: 414418.
  • 12
    Pépin J, Routhier S, Gagnon S, Brazeau I. Management and outcomes of a first recurrence of Clostridium difficile-associated disease in Quebec, Canada. Clin Infect Dis 2006; 42: 758764.
  • 13
    Numan S, Veldkamp P, Kuijper EJ et al. Clostridium difficile-associated diarrhea: bovine anti-Clostridium difficile whey protein to help aid the prevention of relapses. Gut 2007; 56: 888889.
  • 14
    Warny M, Vaerman J-P, Avesani V, Delmée M. Human antibody response to Clostridium difficile toxin A in relation to clinical course of infection. Infect Immun 1994; 62: 384389.
  • 15
    Kyne L, Warny M, Qamar A, Kelly CP. Association between antibody response to toxin A and protection against recurrent Clostridium difficile diarrhea. Lancet 2001; 357: 189193.
  • 16
    Al-Nassir WN, Sethi AK, Riggs MM, Bobulsky GS, Jump RLP, Donskey CJ. A comparison of clinical and microbiologic response to treatment of Clostridium difficile-associated disease with metronidazole and vancomycin. Clin Infect Dis 2008; 47: 5662.
  • 17
    Louie TJ, Peppe J, Watt CK et al. Tolevamer, a novel nonantibiotic polymer, compared with vancomycin in the treatment of mild to moderately severe Clostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43: 411420.
  • 18
    Keighly MRB, Burdon DW, Arabi Y et al. Randomised controlled trial of vancomycin for pseudomembranous colitis and postoperative diarrhoea. BMJ 1978; 2: 16671679.
  • 19
    Teasley DG, Gerding DN, Olson MM et al. Prospective randomised trial of metronidazole versus vancomycin for Clostridium difficile-associated diarrhoea and colitis. Lancet 1983; 2: 10431046.
  • 20
    Young GP, Ward PB, Bayley N et al. Antibiotic-associated colitis due to Clostridium difficile: double-blind comparison of vancomycin with bacitracin. Gastroenterology 1985; 89: 10381045.
  • 21
    Dudley MN, McLaughlin JC, Carrington G et al. Oral bacitracin vs vancomycin therapy for Clostridium difficile-associated diarrhoea. A randomized double-blind trial. Arch Intern Med 1986; 146: 11011104.
  • 22
    Fekety R, Silva J, Kauffman C et al. Treatment of antibiotic-associated Clostridium difficile colitis with oral vancomycin: comparison of two dosage regimens. Am J Med 1989; 86: 1519.
  • 23
    Boero M, Berti E, Morgando A et al. Terapia della colite da Clostridium difficile: Risultati di uno studio randomizzato aperto rifaximina vs. vancomicina. Microbiologia Medica 1990; 5: 7477.
  • 24
    De Lalla F, Nicolin R, Rinaldi E et al. Prospective study of oral teicoplanin versus oral vancomycin for therapy of pseudomembranous colitis and Clostridium difficile-associated diarrhea. Antimicrob Agents Chemother 1992; 36: 21922196.
  • 25
    Wiström J, on behalf of the Swedish CDAD study group. Treatment of Clostridium difficile associated diarrhea and colitis with an oral preparation of teicoplanin; a dose finding study. Scand J Infect Dis 1994; 26: 309316.
  • 26
    Wenisch C, Parschalk B, Hasenhündl M et al. Comparison of vancomycin, teicoplanin, metronidazole, and fusidic acid for the treatment of Clostridium difficile-associated diarrhea. Clin Infect Dis 1996; 22: 813818.
  • 27
    Wullt M, Odenholt I. A double-blind randomized controlled trial of fusidic acid and metronidazole for treatment of an initial episode of Clostridium difficile-associated diarrhoea. J Antimicrob Chemother 2004; 54: 211216.
  • 28
    Musher DM, Logan N, Hamill RJ et al. Nitazoxanide for the treatment of Clostridium difficile colitis. Clin Infect Dis 2006; 43: 421427.
  • 29
    Lagrotteria D, Holmes S, Smieja M et al. Prospective, randomized inpatient study of oral metronidazole versus oral metronidazole and rifampin for treatment of primary episode of Clostridium difficile-associated diarrhea. Clin Infect Dis 2006; 43: 547552.
  • 30
    Louie T, Miller M, Donskey C, Mullane K, Goldstein EJ. Clinical outcomes, safety and pharmacokinetics of OPT-80 in a phase 2 trial of patients with Clostridium difficile infection. Antimicrob Agents Chemother 2009; 53: 223228.
  • 31
    Musher DM, Logan N, Bressler AM, Johnson DP, Rossignol JF. Nitazoxanide versus vancomycin in Clostridium difficile infection: a randomized, double-blind study. Clin Infect Dis 2009; 48: e41e46.
  • 32
    Louie T, Mullane KM, Weiss K et al. A randomized, double-blind clinical trial of OPT-80 versus vancomycin in Clostridium difficile infection (abstract #O148). European Congress of Clinical Microbiology and Infectious Diseases (ECCMID) 2009 in Helsinki, Finland; 2009.
  • 33
    McFarland LV, Surawicz CM, Greenberg RN et al. A randomized placebo-controlled trial of Saccharomyces boulardii in combination with standard antibiotics for Clostridium difficile disease. JAMA 1994; 271: 19131918.
  • 34
    Louie TJ, Gerson M, Grimard D et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhea (CDAD). In: Program and abstracts of the 47th Interscience Conference on Antimicrobial Agents and Chemotherapy, 17 20 September 2007, Chicago, USA. Abstract K-425a.
  • 35
    Bouza E, Dryden M, Mohammed R et al. Results of a phase III trial comparing tolevamer, vancomycin and metronidazole in patients with Clostridium difficile-associated diarrhoea. In: Program and abstracts of the 18th European Congress of Clinical Microbiology and Infectious Diseases, 19 22 April 2008, Barcelona, Spain. Abstract O464.
  • 36
    Lowy I. Phase II Efficacy of Human Monoclonal Antibody Treatment to Prevent C. difficile Recurrence. Oral presentation at Digestive Disease Week in Chicago on June 2, 2009; Abstract 751b.
  • 37
    Bartlett JG, Tedesco FJ, Shull S et al. Symptomatic relapse after oral vancomycin therapy of antibiotic-associated pseudomembranous colitis. Gastroenterology 1980; 78: 431434.
  • 38
    Silva J Jr, Batts DH, Fekety R et al. Treatment of Clostridium difficile colitis and diarrhea with vancomycin. Am J Med 1981; 71: 815822.
  • 39
    Cherry RD, Portnoy D, Jabbari M et al. Metronidazole: an alternate therapy for antibiotic-associated colitis. Gastroenterology 1982; 82: 849851.
  • 40
    Bartlett JG. Treatment of antibiotic-associated pseudomembranous colitis. Rev Infect Dis 1984; 6 (suppl 1): S235S241.
  • 41
    De Lalla F, Privitera G, Rinaldi E et al. Treatment of Clostridium difficile-associated disease with teicoplanin. Antimicrob Agents Chemother 1989; 33: 11251127.
  • 42
    Olson MM, Shanholtzer CJ, Lee JT Jr, Gerding DN. Ten years of prospective Clostridium difficile-associated disease surveillance and treatment at the Minneapolis VA Medical Center, 1982–1991. Infect Control Hosp Epidemiol 1994; 15: 371381.
  • 43
    Musher DM, Aslam S, Logan N et al. Relatively poor outcome after treatment of Clostridium difficile colitis with metronidazole. Clin Infect Dis 2005; 40: 15861590.
  • 44
    Louie TJ. Treating Clostridium difficile in the future: what’s coming? Program and abstracts of the 45th Interscience Conference on Antimicrobial Agents and Chemotherapy; December 16–19, 2005; Washington, DC. Abstract 1774.
  • 45
    Musher DM, Logan N, Mehendiratta V et al. Clostridium difficile colitis that fails conventional metronidazole therapy: response to nitazoxanide. J Antimicrob Chemother 2007; 59: 705710.
  • 46
    Herpers BL, Vlaminckx B, Burkhardt O et al. Tigecycline for severe refractory Clostridium difficile infection. Clin Infect Dis 2009; 48: 17321735.
  • 47
    Mogg GA, George RH, Youngs D et al. Randomised controlled trial of colestipol in antibiotic-associated colitis. Br J Surg 1982; 69: 137139.
  • 48
    Van Dissel JT, De Groot N, Hensgens CM et al. Bovine antibody-enriched whey to aid in the prevention of a relapse of Clostridium difficile associated diarrhoea: preclinical and preliminary clinical data. J Med Microbiol 2005; 54: 197205.
  • 49
    Surawicz CM, McFarland LV, Greenberg RN et al. The search for a better treatment for recurrent Clostridium difficile disease: use of high-dose vancomycin combined with Saccharomyces boulardii. Clin Infect Dis 2000; 31: 10121017.
  • 50
    Wullt M, Hagslätt ML, Odenholt I. Lactobacillus plantarum 299v for the treatment of recurrent Clostridium difficile-associated diarrhoea: a double-blind, placebo-controlled trial. Scand J Infect Dis 2003; 35: 365367.
  • 51
    Lawrence SJ, Korzenik JR, Mundy LM. Probiotics for recurrent Clostridium difficile disease. J Med Microbiol 2005; 54: 905906.
  • 52
    Mattila E, Veli-Jukka A, Broas M et al. A randomized, double-blind study comparing Clostridium difficile immune whey and metronidazole for recurrent Clostridium difficile-associated diarrhoea: efficacy and safety data of a prematurely interrupted trial. Scand J Infect Dis 2008; 40: 702708.
  • 53
    Buggy BP, Fekety R, Silva J Jr. Therapy of relapsing Clostridium difficile-associated diarrhea and colitis with the combination of vancomycin and rifampin. J Clin Gastroenterol 1987; 9: 155159.
  • 54
    Johnson S, Schriever C, Galang M et al. Interruption of recurrent Clostridium difficile-associated diarrhea episodes by serial therapy with vancomycin and rifaximin. Clin Infect Dis 2007; 44: 846848.
  • 55
    Garey KW, Jiang ZD, Bellard A, DuPont HL. Rifaximin in treatment of recurrent Clostridium difficile-associated diarrhea, an uncontrolled pilot study. J Clin Gastroenterol 2009; 43: 9192.
  • 56
    Gorbach SL, Chang TW, Goldin B. Successful treatment of relapsing Clostridium difficile colitis with Lactobacillus GG. Lancet 1987; 2: 1519.
  • 57
    Biller JA, Katz AJ, Flores AF et al. Treatment of recurrent Clostridium difficile colitis with Lactobacillus GG. J Pediatr Gastroenterol Nutr 1995; 21: 224226.
  • 58
    Bowden TA Jr, Mansberger AR Jr, Lykins LE. Pseudomembraneous enterocolitis: mechanism for restoring floral homeostasis. Am Surg 1981; 47: 178183.
  • 59
    Tvede M, Rask-Madsen J. Bacteriotherapy for chronic relapsing Clostridium difficile diarrhoea in six patients. Lancet 1989; 1: 11561160.
  • 60
    Lund-Tønnesen S, Berstad A, Schreiner A, Midtvedt T. Clostridium difficile-associated diarrhea treated with homologous feces. Tidsskr Nor Laegeforen 1998; 118: 10271030.
  • 61
    Aas J, Gessert CE, Bakken JS. Recurrent Clostridium difficile colitis: case series involving 18 patients treated with donor stool administered via a nasogastric tube. Clin Infect Dis 2003; 36: 580585.
  • 62
    Jorup-Rönström C, Håkanson A, Persson AK et al. Feces culture successful therapy in Clostridium difficile diarrhea. Lakartidningen 2006; 103: 36033605.
  • 63
    Nieuwdorp M, Van Nood E, Speelman P et al. Behandeling van recidiverende Clostridium difficile-geassocieerde diarree met een suspensie van donorfeces. Ned Tijdschr Geneeskd 2008; 152: 19271932.
  • 64
    Macconnachie AA, Fox R, Kennedy DR, Seaton RA. Faecal transplant for recurrent Clostridium difficile-associated diarrhoea: a UK case series. QJM 2009; 102: 781784.
  • 65
    Leung DAY, Kelly CP, Boguniewicz M et al. Treatment with intravenously administered gamma globulin of chronic relapsing colitis induced by Clostridium difficile toxin. J Pediatr 1991; 118: 633637.
  • 66
    Beales IL. Intravenous immunoglobulin for recurrent Clostridium difficile diarrhoea. Gut 2002; 51: 456.
  • 67
    Wilcox MH. Descriptive study of intravenous immunoglobulin for the treatment of recurrent Clostridium difficile diarrhoea. J Antimicrob Chemother 2004; 53: 882884.
  • 68
    McPherson S, Rees CJ, Ellis R, Soo S, Panter SJ. Intravenous immunoglobulin for the treatment of severe, refractory, and recurrent Clostridium difficile diarrhea. Dis Colon Rectum 2006; 49: 640645.
  • 69
    Bakken S. Novel therapies for Clostridium difficile disease. In: Program and abstracts of the 45th Annual Meeting of the Infectious Disease Society of America, 4 7 October 2007, San Diego, USA. Oral session 611.
  • 70
    Nelson R. Antibiotic treatment for Clostridium difficile-associated diarrhea in adults. Cochrane Database Syst Rev 2007; CD004610. DOI: 10.1002/14651858.CD004610.pub3.
  • 71
    Anonymous. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. Health Protection report, 2008: 2: January 18th. Available at: http://www.hpa.org.uk/hpr/archives/2008/news0308.htm#cdiff1.
  • 72
    Baines SD, O’Connor R, Freeman J et al. Emergence of reduced susceptibility to metronidazole in Clostridium difficile. J Antimicrob Chemother 2008; 62: 10461052.
  • 73
    Nagy E, Földes J. Inactivation of metronidazole by Enterococcus faecalis. J Antimicrob Chemother 1991; 27: 6370.
  • 74
    Pillai A, Nelson R. Probiotics for treatment of Clostridium difficile-associated colitis in adults. Cochrane Database Syst Rev 2008; CD004611. DOI: DOI: 10.1002/14651858.CD004611.pub2.
  • 75
    Bassetti S, Frei R, Zimmerli W. Fungemia with Saccharomyces cerevisiae after treatment with Saccharomyces boulardii. Am J Med 1998; 105: 7172.
  • 76
    Muñoz P, Bouza E, Cuenca-Estrella M et al. Saccharomyces cerevisiae fungemia: an emerging infectious disease. Clin Infect Dis 2005; 40: 16251634.
  • 77
    Besselink MG, Van Santvoort HC, Buskens E et al. Probiotic prophylaxis in predicted severe acute pancreatitis: a randomised, double-blind, placebo-controlled trial. Lancet 2008; 371: 651659.
  • 78
    Friedenberg F, Fernandez A, Kaul V et al. Intravenous metronidazole for the treatment of Clostridium difficile colitis. Dis Colon Rectum 2001; 44: 11761180.
  • 79
    Lamontage F, Labbe AC, Kaeck O et al. Impact of emergency colectomy on survival of patients with fulminant Clostridium difficile colitis during an epidemic caused by a hypervirulent strain. Ann Surg 2007; 245: 267272.
  • 80
    Kato H, Kato H, Iwashima Y, Nakamura M, Nakamura A, Ueda R. Inappropriate use of loperamide worsens Clostridium difficile-associated diarrhoea. J Hosp Infect 2008; 70: 194195.
  • 81
    Vonberg R-P, Kuijper EJ, Wilcox MH et al. Infection control measures to limit the spread of Clostridium difficile. Clin Microbiol Infect 2008; 14 (suppl 5): 220.